The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control

Ann Oncol. 2010 Feb;21(2):426-428. doi: 10.1093/annonc/mdp527. Epub 2009 Nov 9.
No abstract available

Publication types

  • Evaluation Study
  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Chlorambucil / administration & dosage
  • Chlorambucil / adverse effects
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Humans
  • Lomustine / administration & dosage*
  • Lomustine / adverse effects
  • Palliative Care
  • Patient Satisfaction*
  • Prednisolone / administration & dosage
  • Prednisolone / adverse effects
  • Survival Analysis
  • Survivors
  • Time Factors

Substances

  • Chlorambucil
  • Etoposide
  • Lomustine
  • Prednisolone